Table 2 KRAS status as a predictive marker in lung cancer
From: KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Reference | Patients tested for KRAS | Patients by KRAS status | Treatment arm | Endpoint | KRAS-mut | KRAS-wt | |
|---|---|---|---|---|---|---|---|
KRAS-mut | KRAS-wt | ||||||
Rodenhius et al., 1997 [68] | 62 (stage III-IV) | 16 | 46 | Carboplatin + ifosfamide + etoposide | ORR (%) | 19 | 26 |
PFS (months) | 4 | 5 | |||||
OS (months) | 8 | 9 | |||||
Schiller et al., 2001 [69] | 184 (stage II-IIIA) | 44 | 140 | Cisplatin + etoposide | OS (months) | 24.7 | 42 |
Eberhard et al., 2005 [70] | 133 (advanced stage) | 25 | 108 | Carboplatin + paclitaxel + erlotinib | ORR (%) | 23 | 26 |
PFS (months) | 6.0 | 5.4 | |||||
OS (months) | 13.5 | 11.3 | |||||
Tsao et al., 2007 [71] | 210 (stage Ib-II) | 46 | 164 | Vinorelbine + cisplatin | OS (months) | 6.4 | NR |
Mao et al., 2010 [76] | 1470 (stage NS) | 231 | 1239 | EGFR TKI | ORR (%) | 3 | 26 |
Khambata-Ford et al., 2010 [82] | 202 (stage IIIB, IV) | 35 | 167 | Taxane + carboplatin + cetuximab | ORR (%) | 30.8 | 32.9 |
PFS (months) | 5.6 | 5.1 | |||||
OS (months) | 16.8 | 9.7 | |||||
O’Byrne KJ et al., 2011 [83] | 395 (stage IIIB, IV) | 75 | 320 | Cisplatin + vinorelbine + cetuximab | ORR (%) | 36.8 | 37.3 |
PFS (months) | 5.4 | 4.4 | |||||
OS (months) | 8.9 | 11.4 | |||||
Ludovini V et al., 2011 [79] | 166 (stage III, IV) | 11 | 151 | EGFR TKI | ORR (%) | 0 | 35.7 |
PFS (months) | 2.7 | 5.6 | |||||
OS (months) | 19.3 | 28.6 | |||||
Metro et al., 2012 [81] | 67 (stage IIIB-IV) | 18 | 49 | EGFR TKI (gefitinib or erlotinib) | PFS (months) | 1.6 | 3.0 |
OS (months) | 6.0 | 21.0 | |||||
Fiala O et al., 2013 [80] | 448 (stage IIIB, IV) | 138 (G12C mutation: 38) | 410 | EGFR TKI | PFS (weeks) | 4.3 (G12C) vs 9.0 (non-G12C) | |
OS (weeks) | 12.1 (G12C) vs 9.3 (non-G12C) | ||||||
Zer et al., 2016 [63] | 785 (stage IIIB-IV) | 155 | 630 | EGFR TKI (pooled analysis) | OS (months) | 4.5 | 6.0 |
Hames ML et al., 2016 [73] | 150 (stage IV) | 80 | 70 | Conventional chemotherapy | PFS (months) | 4.5 | 5.7 |
OS (months) | 8.8 | 13.5 | |||||
Dong ZY et al., 2017 [84] | 34 (not specified) | 8 | 26 | Pembrolizumab | ORR (%) | 25 | 6.6 |
20 (not specified) | 5 | 15 | Pembrolizumab or nivolumab | PFS (months) | 14.7 | 3.5 | |